could protect macaques against lung disease following a single immunisation. Currently, participants are being enrolled for the next phase of human trials, with the hope that an effective vaccine could be generated later this year.
The Pirbright studies were intended to determine if two doses – prime and boost – of the new vaccine trigger a greater immune response in pigs.
An enhanced immune response is set to offer improved protection against the disease.According to the study findings, two ChAdOx1 nCoV-19 vaccine doses induce a significantly greater antibody response in pigs, with a significant rise in neutralising antibodies that bind to the virus and block infection.